{"id":7021,"date":"2025-03-31T15:04:16","date_gmt":"2025-03-31T15:04:16","guid":{"rendered":"https:\/\/stoxpo.com\/?p=7021"},"modified":"2025-03-31T15:04:17","modified_gmt":"2025-03-31T15:04:17","slug":"biotech-stocks-slide-as-fdas-peter-marks-resigns","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/03\/31\/biotech-stocks-slide-as-fdas-peter-marks-resigns\/","title":{"rendered":"Biotech Stocks Slide as FDA\u2019s Peter Marks Resigns"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Wall Street Reacts to Leadership Uncertainty in Biopharma Approvals<\/h4>\n\n\n\n<p>The resignation of Peter Marks, director of the FDA\u2019s Center for Biologics Evaluation and Research (CBER), sent biotech stocks tumbling on Monday, as investors worried about the future of regulatory approvals in the sector.<\/p>\n\n\n\n<p>Marks, who played a key role in approving COVID-19 and RSV vaccines, cited concerns over the anti-vaccine stance of Health and Human Services Secretary Robert F. Kennedy Jr. and the ability of the new FDA head, Marty Makary, to resist such influences. His departure, effective April 5, has created uncertainty about the agency\u2019s regulatory flexibility and future drug approvals.<\/p>\n\n\n\n<p>Vaccine stocks were hit hardest, with Moderna (MRNA) plunging more than 10% in early trading. Novavax (NVAX) dropped over 8%, BioNTech (BNTX) fell more than 7%, while Dynavax (DVAX) and Vaxcyte (PCVX) declined 2% and 54%, respectively. Broader biotech losses included Gilead Sciences (GILD), which initially fell over 4% before recovering some ground.<\/p>\n\n\n\n<p>Wall Street analysts warned of heightened risks for rare disease and cell and gene therapy companies, given their reliance on FDA support for novel product approvals. Jefferies analyst Michael Yee noted that concerns over Marks\u2019s resignation had already driven biotech stocks down more than 20% year-to-date.<\/p>\n\n\n\n<p>Despite the market reaction, some strategists, including Mizuho\u2019s Jared Holz, cautioned against assuming the worst, suggesting that while Marks\u2019s exit raises concerns, the broader impact on biotech innovation remains uncertain.<\/p>\n\n\n\n<p>With the FDA\u2019s transparency in question, investors are now watching closely for news on Marks\u2019s successor and how the regulatory landscape will evolve under new leadership.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/03\/31\/bitcoin-microstrategy-and-coinbase-strong-buying-opportunities-amid-the-dip\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Bitcoin, MicroStrategy, and Coinbase: Strong Buying Opportunities Amid the Dip<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wall Street Reacts to Leadership Uncertainty in Biopharma Approvals The resignation of Peter Marks, director of the FDA\u2019s Center for Biologics Evaluation and Research (CBER), sent biotech stocks tumbling on Monday, as investors worried about the future of regulatory approvals in the sector. Marks, who played a key role in approving COVID-19 and RSV vaccines, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1127,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[308,361],"tags":[473,421,462,416,418,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7021"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=7021"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7021\/revisions"}],"predecessor-version":[{"id":7023,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7021\/revisions\/7023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1127"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=7021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=7021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=7021"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=7021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}